Clinical Trials Browser

ribociclib × Breast × Clear all

NCT04862663 2026-05-27

CAPItello-292

Phase 3 Recruiting

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT05870579 2026-05-27

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT06953882 2026-05-26

SELECT

Phase 2 Recruiting

HER2 Negative Breast Cancer

NCT07054190 2026-05-26

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07237256 2026-05-26

NoLEEta

Phase 3 Recruiting

Breast Neoplasms

NCT05768139 2026-05-22

PIKALO-1

Phase 1/2 Recruiting

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06930859 2026-05-22

ELEGANCE

Breast Neoplasms

NCT07174336 2026-05-22

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07492641 2026-05-22

KANDELA-302

Phase 3 Recruiting

HR+/HER2- Breast Cancer

NCT06760637 2026-05-19

FourLight-3

Phase 3 Active not recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07405801 2026-05-18

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06380751 2026-05-15

EvoPAR-BR01

Phase 3 Recruiting

Advanced Breast Cancer

NCT07085767 2026-05-15

OPERA-02

Phase 3 Recruiting

Breast Neoplasms

NCT05296746 2026-05-14

RIBOLARIS

Phase 2 Active not recruiting

Breast Neoplasms

NCT05827081 2026-05-14

Adjuvant WIDER

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT06377852 2026-05-13

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Phase 3 Recruiting

Breast Neoplasms

NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Phase 3 Not yet recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT04055493 2026-05-11

ADAPTcycle

Phase 3 Active not recruiting

Breast Neoplasms

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT06188520 2026-05-11

CYCAD-1

Phase 1/2 Recruiting

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT06830720 2026-05-08

CAROLEEN

Breast Neoplasms

NCT06075758 2026-05-06

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Breast Neoplasms

NCT06065748 2026-05-05

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06905301 2026-05-05

IMPULSE

Breast Neoplasms

NCT03616587 2026-04-30

SERENA-1

Phase 1 Active not recruiting

Breast Neoplasms

NCT07400523 2026-04-28

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3 Recruiting

Breast Neoplasms

NCT06726148 2026-04-27

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

Breast Neoplasms

NCT05683418 2026-04-22

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04964934 2026-04-21

SERENA-6

Phase 3 Active not recruiting

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05664893 2026-04-15

CALHYS

Phase 1/2 Withdrawn

HER2 Negative Breast Cancer Not Immediately Operated

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Breast Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07164976 2026-04-13

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT05467891 2026-04-08

RaPhLRR

Phase 2 Recruiting

Locoregional Recurrence

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

Breast Neoplasms

NCT07340658 2026-04-02

SIE-3

Phase 3 Not yet recruiting

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

Phase 3 Active not recruiting

5,101 enrolled 1 FDA

Breast Neoplasms

NCT04943497 2026-04-01

PROSPERITY

Breast Neoplasms

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT05697146 2026-03-16

RosaLEE

Active not recruiting

Breast Neoplasms

NCT02712723 2026-03-11

FELINE

Phase 2 Active not recruiting

121 enrolled 9 charts

Breast Neoplasms

NCT05573555 2026-03-09

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT06797531 2026-02-04

NISLEESA

Breast Neoplasms

NCT05996107 2026-01-28

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms